Terms: = Skin cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Treatment
10517 results:
1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
2. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
3. Hospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17-year retrospective study.
Amonchaisakda N; Rujitharanawong C; Tuchinda P; Kulthanan K; Chularojanamontri L
Exp Dermatol; 2024 May; 33(5):e15095. PubMed ID: 38742822
[TBL] [Abstract] [Full Text] [Related]
4. [Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data].
Stoyukhina AS
Vestn Oftalmol; 2024; 140(2. Vyp. 2):16-20. PubMed ID: 38739126
[TBL] [Abstract] [Full Text] [Related]
5. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
[TBL] [Abstract] [Full Text] [Related]
6. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract] [Full Text] [Related]
7. An Explorative Study on Calcium Electroporation for Low-risk Basal Cell Carcinoma.
Wiegell SR; Hendel K; Fuchs CSK; Gehl J; Vissing M; Bro SW; Troelsen JT; Jemec GBE; Haedersdal M
Acta Derm Venereol; 2024 May; 104():adv19678. PubMed ID: 38712969
[TBL] [Abstract] [Full Text] [Related]
8. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
9. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
[TBL] [Abstract] [Full Text] [Related]
10. Age group-specific changes in keratinocyte cancer treatment rates in Australia, 2012-2021: a retrospective cohort study based on MBS claims data.
Olsen CM; Pandeya N; Neale RE; Whiteman DC
Med J Aust; 2024 May; 220(9):472-479. PubMed ID: 38685827
[TBL] [Abstract] [Full Text] [Related]
11. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract] [Full Text] [Related]
12. Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage.
Yetkin-Arik B; Jansen SA; Varderidou-Minasian S; Westendorp B; Skarp KP; Altelaar M; Lindemans CA; Lorenowicz MJ
Stem Cell Res Ther; 2024 Apr; 15(1):125. PubMed ID: 38679715
[TBL] [Abstract] [Full Text] [Related]
13. Complications and Recurrences after Excision and Reconstruction of Eyelid Tumours.
Balchev G
Curr Oncol; 2024 Mar; 31(4):1713-1724. PubMed ID: 38668033
[TBL] [Abstract] [Full Text] [Related]
14. Uveal melanoma incidence and survival analysis in Portugal between 2013 and 2022.
Geada S; Machado T; Teixeira T; Simões PC; Oliveiros B; da Luz Cachulo M; Fonseca C; Proença R
Cancer Epidemiol; 2024 Jun; 90():102575. PubMed ID: 38663175
[TBL] [Abstract] [Full Text] [Related]
15. Dermoscopic-Guided Shave Removal of Acquired Facial Melanocytic Nevi in Dark-skinned Individuals.
Rezk AF; Touni AA
Dermatol Surg; 2024 May; 50(5):434-438. PubMed ID: 38662517
[TBL] [Abstract] [Full Text] [Related]
16. skin Changes in Suspected Lyme Disease.
Vržogić P; Perica A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):225-228. PubMed ID: 38651851
[TBL] [Abstract] [Full Text] [Related]
17. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract] [Full Text] [Related]
18. Cutaneous T-cell Lymphomas: A Single-center Retrospective Analysis.
Kaemmerer T; Guertler A; Clanner-Engelshofen BM; Fuchs C; French LE; Reinholz M
Acta Dermatovenerol Croat; 2023 Dec; 31(4):184-190. PubMed ID: 38651844
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
Thet Z; Lam AK; Ng SK; Aung SY; Han T; Ranganathan D; Newsham S; Borg J; Pepito C; Khoo TK
Aust J Rural Health; 2024 Apr; 32(2):249-262. PubMed ID: 38646861
[TBL] [Abstract] [Full Text] [Related]
20. The role of thymic stromal lymphopoietin in cutaneous disorders.
Jafari AJ; Rivera M; Hebert AA
Arch Dermatol Res; 2024 Apr; 316(5):123. PubMed ID: 38630260
[TBL] [Abstract] [Full Text] [Related]
[Next]
